ADC Therapeutics Future Growth
Future criteria checks 2/6
ADC Therapeutics is forecast to grow earnings and revenue by 28.5% and 29.2% per annum respectively while EPS is expected to grow by 34.5% per annum.
Key information
28.5%
Earnings growth rate
34.5%
EPS growth rate
Biotechs earnings growth | 21.1% |
Revenue growth rate | 29.2% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
Aug 09Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts
Jul 21Sobi to pay ADC Therapeutics $55M upfront to license Zynlonta in Europe, other regions
Jul 08ADC Therapeutics begins dosing in study of Zynlonta combo for blood cancer subtype
Jun 29Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?
Jun 22ADC Therapeutics SA (NYSE:ADCT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 06Growth Investors: Industry Analysts Just Upgraded Their ADC Therapeutics SA (NYSE:ADCT) Revenue Forecasts By 21%
Mar 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 146 | -135 | -18 | N/A | 4 |
12/31/2025 | 94 | -171 | -89 | -134 | 5 |
12/31/2024 | 81 | -183 | -111 | -155 | 6 |
12/31/2023 | 70 | -240 | -122 | -119 | N/A |
9/30/2023 | 123 | -179 | -141 | -138 | N/A |
6/30/2023 | 184 | -181 | -104 | -101 | N/A |
3/31/2023 | 182 | -199 | -120 | -118 | N/A |
12/31/2022 | 210 | -157 | -139 | -138 | N/A |
9/30/2022 | 157 | -166 | -149 | -146 | N/A |
6/30/2022 | 94 | -187 | -212 | -207 | N/A |
3/31/2022 | 80 | -195 | -219 | -212 | N/A |
12/31/2021 | 34 | -230 | -240 | -233 | N/A |
9/30/2021 | 17 | -252 | -230 | -223 | N/A |
6/30/2021 | 4 | -200 | -215 | -209 | N/A |
3/31/2021 | N/A | -254 | -195 | -192 | N/A |
12/31/2020 | N/A | -246 | -172 | -169 | N/A |
9/30/2020 | N/A | -226 | -153 | -151 | N/A |
6/30/2020 | N/A | -237 | -140 | -139 | N/A |
3/31/2020 | 1 | -135 | -128 | -126 | N/A |
12/31/2019 | 2 | -116 | -124 | -122 | N/A |
9/30/2019 | 3 | -112 | -121 | -118 | N/A |
6/30/2019 | 3 | -111 | -119 | -116 | N/A |
3/31/2019 | 2 | -117 | -122 | -118 | N/A |
12/31/2018 | 1 | -123 | -124 | -121 | N/A |
12/31/2017 | 2 | -90 | -78 | -75 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADCT's revenue (29.2% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: ADCT's revenue (29.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADCT's Return on Equity is forecast to be high in 3 years time